Mr. Christopher P. Kiritsy

• 
  www.arisaph.com/about/management.php - [Cached Version]
  Published on: 4/1/2009    Last Visited: 4/1/2009  

  - Christopher P. Kiritsy, Co-Founder, President and Chief Executive Officer
  ...
  Christopher Kiritsy President and Chief Executive Officer, Co-Founder
  
  Mr. Kiritsy, a co-founder, joined the Company as President and Chief Executive Officer in June of 2005 and has served as a Director since inception. Mr. Kiritsy is a seasoned entrepreneur, who possesses 20 years of unique business and technical experience, previously holding senior management positions in R&D, business development and finance. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played an integral role in building Kos from a small development organization into a highly profitable, 1,500 person, fully-integrated pharmaceutical company with annual sales approaching $1 billion. During his 10 year tenure at Kos, Mr. Kiritsy raised approximately $500 million in public equity capital, including Kos' IPO, and spearheaded in excess of 10 corporate development transactions. He also played a key operating role in commercializing Kos' two internally developed cholesterol therapies (Niaspan® and Advicor®) and in delivering financial results that consistently exceeded Wall Street expectations. In 2005, Fortune Magazine ranked Kos the fastest growing pharmaceutical company and 6th fastest growing company overall in the United States.
  
  Prior to Kos, Mr. Kiritsy served as Associate Director of Product Development at the Institute of Molecular Biology, a private biotechnology company, where he co-authored several publications in scientific journals. Mr. Kiritsy received an A.B. from Bowdoin College in Biology and an M.B.A. from Boston University.

• 
  www.sec.gov/Archives/edgar/data/1018952/0001021408-02-0 - [Cached Version]
  Published on: 3/19/2002    Last Visited: 6/28/2002  

  Christopher P. Kiritsy Senior Vice President, Chief Financial Officer
  
  ...
  Christopher P. Kiritsy joined KOS PHARMACEUTICALS INC in June 1995 and currently serves as Senior Vice President, Chief Financial Officer.Since joining Kos, Mr. Kiritsy has been instrumental in executing various business development and financing activities, including Kos' two public equity offerings completed during 1997.From 1988 to 1995, Mr. Kiritsy served as Associate Director of Product Development at the Institute of Molecular Biology, a private biotechnology company.

• 
  www.arisaph.com/about/directors.php - [Cached Version]
  Published on: 4/1/2009    Last Visited: 4/1/2009  

  Christopher Kiritsy Co-Founder, President and Chief Executive Officer
  
  Mr. Kiritsy, a co-founder, joined the Company as President and Chief Executive Officer in June of 2005 and has served as a Director since inception. Mr. Kiritsy is a seasoned entrepreneur, who possesses 20 years of unique business and technical experience, previously holding senior management positions in R&D, business development and finance. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played an integral role in building Kos from a small development organization into a highly profitable, 1,500 person, fully-integrated pharmaceutical company with annual sales approaching $1 billion. During his 10 year tenure at Kos, Mr. Kiritsy raised approximately $500 million in public equity capital, including Kos' IPO, and spearheaded in excess of 10 corporate development transactions. He also played a key operating role in commercializing Kos' two internally developed cholesterol therapies (Niaspan® and Advicor®) and in delivering financial results that consistently exceeded Wall Street expectations. In 2005, Fortune Magazine ranked Kos the fastest growing pharmaceutical company and 6th fastest growing company overall in the United States.
  
  Prior to Kos, Mr. Kiritsy served as Associate Director of Product Development at the Institute of Molecular Biology, a private biotechnology company, where he co-authored several publications in scientific journals. Mr. Kiritsy received an A.B. from Bowdoin College in Biology and an M.B.A. from Boston University.

• 
  www.arisaph.com/about/management.php - [Cached Version]
  Published on: 4/1/2009    Last Visited: 4/1/2009  

  Chris Kiristy

• 
  www.biospace.com/news_story.aspx?NewsEntityId=99496&Sou - [Cached Version]
  Published on: 6/8/2008    Last Visited: 6/9/2008  

  "We are very excited about the results demonstrating that ARI-2243 is a multi-mediator, possessing both DPP 4 dependent and independent glucose lowering effects," commented Christopher P. Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals.
  ...
  CONTACT: Christopher Kiritsy, President and CEO, Arisaph Pharmaceuticals,Inc., +1-617-292-3322

• 
  biz.yahoo.com/prnews/080608/nesu001.html?.v=28 - [Cached Version]
  Published on: 6/8/2008    Last Visited: 6/8/2008  

  "We are very excited about the results demonstrating that ARI-2243 is a multi-mediator, possessing both DPP 4 dependent and independent glucose lowering effects," commented Christopher P. Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals.

• 
  www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/w - [Cached Version]
  Published on: 3/11/2008    Last Visited: 3/11/2008  

  company," said Christopher P. Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals.

• 
  diabetic.toptrendweb.com/2008/05/page/2/ - [Cached Version]
  Last Visited: 6/23/2008  

  "In ARI-2243, we have designed a smart, long acting DPP-4 inhibitor that is extremely potent and functionally selective," comment Christopher P. Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals.

• 
  www.dimag.com/pacswebcardio/pressreleases/showPressRele - [Cached Version]
  Published on: 6/25/2007    Last Visited: 6/25/2007  

  "In ARI-2243, we have designed a smart, long acting DPP-4 inhibitor that is extremely potent and functionally selective," commented Christopher P. Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals.
  ...
  CONTACT: Christopher Kiritsy, President and CEO of ArisaphPharmaceuticals, Inc., +1-617-292-3322 Web site: http://www.arisaph.com/

• 
  www.rehabpub.com/press_release.asp?id=10082790 - [Cached Version]
  Published on: 6/25/2007    Last Visited: 6/26/2007  

  "In ARI-2243, we have designed a smart, long acting DPP-4 inhibitor that is extremely potent and functionally selective," commented Christopher P. Kiritsy, President and Chief Executive Officer of Arisaph Pharmaceuticals.

Page:  1 2 3 4 5